Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

MLA

Daver, Naval, et al. “Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML).” Blood, vol. 140, no. 1, Number 1 Supplement 1, Nov. 2022, pp. 145–49. EBSCOhost, https://doi.org/10.1182/blood-2022-158030.

APA

Daver, N., Montesinos, P., Aribi, A., Marconi, G., Altman, J. K., Wang, E. S., Roboz, G. J., Burke, P. W., Gaidano, G., Walter, R. B., Thomas, X., Jeyakumar, D., DeAngelo, D. J., Erba, H. P., Todisco, E., Begna, K. H., Advani, A., Gastaud, L., De La Fuente, A., … Sweet, K. (2022). Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML). Blood, 140(1, Number 1 Supplement 1), 145–149. https://doi.org/10.1182/blood-2022-158030

Chicago

Daver, Naval, Pau Montesinos, Ahmed Aribi, Giovanni Marconi, Jessica K. Altman, Eunice S. Wang, Gail J. Roboz, et al. 2022. “Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML).” Blood 140 (1, Number 1 Supplement 1): 145–49. doi:10.1182/blood-2022-158030.